Melphalan

CAS 148-82-3 4 current recordsSmall Molecule

Who holds supplier records for Melphalan? 4 organisations hold a current record for Melphalan: an active US FDA Type II Drug Master File or a CEP. 2 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (1), United States (1) and Italy (1); not recorded for 1.

Most records are filed under another form of this substance: Melphalan Hydrochloride (10 current sources). A DMF or CEP is listed under the form it names.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Melphalan: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/melphalan

Reading the evidence

  • 4 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 2 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Melphalan expires 29 Jun 2036. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (4)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Melphalan. Country is the organisation's recorded country, not necessarily the manufacturing site.

India1United States1Italy1Country not recorded for 1
Need Melphalan sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (2)

Certificates of Suitability on the EDQM register for Melphalan, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

HolderCountryCertificateIssuedEU GMP at holder's address
HUBEI HONCH PHARMACEUTICAL CO., LTD. HuanggangCN
CEP 2023-324 - Rev 00
Melphalan
Oct 2024Inspected Feb 2025
Switzerland
BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. HyderabadIN
CEP 2017-238 - Rev 01
Melphalan
Jan 2024—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (15 listed products contain Melphalan). The latest listed patent expires 29 Jun 2036. The latest listed exclusivity runs to 14 Aug 2030. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Melphalan is a bifunctional alkylating agent used in the treatment of multiple myeloma and other types of cancer. It works by causing cross-links in the DNA, leading to cell death.

Therapeutic areas

Oncology

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Melphalan?

4 organisations hold an active US FDA Type II Drug Master File or a CEP for Melphalan: BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (India), HUBEI HONCH PHARMACEUTICAL CO LTD, CHEMPACIFIC CORP (United States) and INDENA SPA (Italy). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Melphalan Drug Master Files are active?

BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (DMF 28300), HUBEI HONCH PHARMACEUTICAL CO LTD (DMF 38591), CHEMPACIFIC CORP (DMF 20073) and INDENA SPA (DMF 44772). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

Does Melphalan have a European Certificate of Suitability?

Yes. 2 organisations hold a valid CEP for Melphalan on the EDQM register, including HUBEI HONCH PHARMACEUTICAL CO., LTD. Huanggang (CN) and BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. Hyderabad (IN). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Melphalan?

Yes. The latest patent listed for an approved US product containing Melphalan expires 29 Jun 2036, across 15 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Melphalan supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Melphalan?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.